Neurocrine Biosciences, Inc. (NBIX) Insider Sells $723,195.00 in Stock
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Darin Lippoldt sold 9,900 shares of the company’s stock in a transaction on Wednesday, November 15th. The stock was sold at an average price of $73.05, for a total transaction of $723,195.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Neurocrine Biosciences, Inc. (NASDAQ NBIX) traded down $0.02 during trading on Friday, hitting $72.28. 866,071 shares of the stock were exchanged, compared to its average volume of 1,122,800. The company has a quick ratio of 14.37, a current ratio of 14.38 and a debt-to-equity ratio of 1.05. Neurocrine Biosciences, Inc. has a one year low of $37.35 and a one year high of $75.98.
Neurocrine Biosciences (NASDAQ:NBIX) last posted its earnings results on Wednesday, November 1st. The company reported ($0.13) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.49) by $0.36. The firm had revenue of $60.77 million for the quarter, compared to analysts’ expectations of $29.38 million. During the same quarter in the prior year, the company posted ($0.43) earnings per share. sell-side analysts predict that Neurocrine Biosciences, Inc. will post -1.74 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: “Neurocrine Biosciences, Inc. (NBIX) Insider Sells $723,195.00 in Stock” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/11/17/neurocrine-biosciences-inc-nbix-insider-sells-723195-00-in-stock.html.
Several brokerages recently issued reports on NBIX. BMO Capital Markets upped their target price on shares of Neurocrine Biosciences from $75.00 to $84.00 and gave the stock an “outperform” rating in a research report on Friday, August 4th. Oppenheimer Holdings, Inc. upped their target price on shares of Neurocrine Biosciences from $70.00 to $85.00 and gave the stock an “outperform” rating in a research report on Thursday, November 2nd. Piper Jaffray Companies set a $68.00 target price on shares of Neurocrine Biosciences and gave the stock a “buy” rating in a research report on Thursday, August 24th. Citigroup Inc. restated a “buy” rating and set a $79.00 price target on shares of Neurocrine Biosciences in a research report on Thursday, November 2nd. Finally, Needham & Company LLC restated a “buy” rating and set a $86.00 price target on shares of Neurocrine Biosciences in a research report on Thursday, November 2nd. One analyst has rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $78.88.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.